VISOR for removing 1–3 cm kidney and ureter stones
Official title: A Single-Center Clinical Study on the Efficacy and Safety of Vortex Intelligence Stone Optimized Removal (VISOR)
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT07071948 · Data updated 2026-11-12
This will test a new device called VISOR to break up and remove 1–3 cm kidney or ureter stones in adults aged 18–80.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | August 6, 2025 |
| Main results expected | October 31, 2025 |
| Study ends | February 28, 2027 |
| Registry record updated | September 26, 2025 |
| Trial ID | NCT07071948 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 with upper urinary tract stones totaling 1–3 cm who opt for flexible ureteroscopic holmium laser lithotripsy and can give informed consent are ideal candidates.
✕Probably not a fit
Patients with ureteral strictures, prior open or laparoscopic renal/ureter surgery, recent fever from infection, pregnant or lactating women, or those with ASA class >3 are excluded and unlikely to benefit in this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This single-center interventional study uses the VISOR multifunctional integrated flexible ureteroscope during flexible ureteroscopic holmium laser lithotripsy to break and remove upper urinary tract stones 1–3 cm in size. During surgery VISOR's features—flushing/suction, pressure control, and simultaneous stone fragmentation/removal—are used and intrarenal pressure is monitored to keep it below 30 mmHg. Success is defined as stone fragments <4 mm on a CT scan obtained within 24 hours after surgery, and safety is tracked by recording serious complications through a 4-week follow-up visit. The trial aims to see if at least 90% of participants are stone-free within 24 hours and if serious adverse events occur in no more than 5% of cases.
Why it matters
Potential benefit: If successful, VISOR could increase the share of patients who are quickly stone-free after ureteroscopic surgery while reducing pressure-related complications.
How similar studies have gone: Some ureteroscopes with suction and pressure-control features have shown promising results in small studies, but VISOR's particular combination of functions is relatively new and less well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients with upper urinary tract calculi, where the maximum diameter of a single calculus or the cumulative diameter of multiple calculi is 1-3 cm 2. Patients who choose to undergo "flexible ureteroscopic holmium laser lithotripsy" 3. Aged 18-80 years, regardless of gender 4. Subjects without mental illness or language dysfunction, who can understand the details of this study and sign the informed consent form Exclusion Criteria: 1. Patients with ureteral stricture or a history of ureteral stricture 2. Patients with a history of open renal and/or ureteral surgery or laparoscopic surgery 3. Fever (body temperature ≥ 38℃) due to urinary tract infection or other reasons within one week before surgery 4. Pregnant women, lactating women, or women who are in the menstrual period 5. ASA classification \> Grade 3: patients with severe systemic diseases, heart diseases, pulmonary insufficiency, and failure of important organ functions, etc., who cannot tolerate anesthesia or surgery 6. Patients with anatomical malformations such as polycystic kidney, horseshoe kidney, and ectopic kidney 7. Patients with abnormal coagulation function (e.g., international normalized ratio (INR) \> 1.5 or platelet count \< 80 × 10⁹/L) 8. Patients with failed sheath placement during surgery
Where it's running
-
2nd Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China Recruiting
Study contacts
- Principal investigator: Bohan Wang, MD., Ph.D — 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
- Study coordinator: Bohan Wang, MD., Ph.D
- Email: wangbohan@zju.edu.cn
- Phone: +86-13575799866
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating how the gut absorbs oxalate in kidney stone patients
This study is trying to see if people with kidney stones absorb more oxalate from their diet than healthy individuals, which might lead to more oxalate in their urine.
-
Using gut bacteria to reduce urinary oxalate in kidney stone patients
This study is testing if introducing a specific gut bacteria can help adults with calcium oxalate kidney stones lower the amount of oxalate in their urine.
-
Emergency urinary drainage followed by PCNL in obstructive urosepsis
Doctors test whether the method of emergency drainage (retrograde ureteral stent or percutaneous nephrostomy) affects how well patients do after undergoing definitive PCNL.
-
Observation vs Upfront Surgery for Asymptomatic Kidney Stones in Children and Adults
This trial tests whether watching asymptomatic kidney stones or performing upfront surgery is better for reducing life disruption in patients aged 6 and older.
-
Two-Tier Virtual Reality Education to Reduce Anxiety Before Kidney Stone Surgery
This study tests whether a two-tier VR preoperative education approach can lower anxiety and improve knowledge and self-care in adults undergoing urolithiasis surgery.
-
Tamsulosin 0.4 mg with Tadalafil 5 mg versus 2.5 mg to reduce symptoms from ureteral stents
This will test whether adding Tadalafil at 5 mg or 2.5 mg to Tamsulosin 0.4 mg better reduces stent-related symptoms for adults with a double-J ureteral stent after stone removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.